MedTrace Logo

A Seamless Phase II/III, Observer-blind, to Evaluate Immunogenicity and Safety of Chikungunya Virus Vaccine in Healthy Subjects 12-65Years of Age.

NCT07555392 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2026-04-29

No results posted yet for this study

Summary

A Seamless Phase II/III, Observer-blind, Multi-centre, Randomized Clinical Trial to Evaluate Immunogenicity and Safety of BBV87, an Inactivated Chikungunya Virus Vaccine in Healthy Subjects 12-65 Years of Age

Conditions

  • Active Immunisation for Chikungunya Virus Infection

Interventions

BIOLOGICAL

BBV87 Chikungunya vaccine

Inactivated Chikungunya Virus Vaccine (BBV87)

BIOLOGICAL

Placebo

Placebo or normal Saline (0.9% )

Sponsors & Collaborators

  • Bharat Biotech International Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-20
Primary Completion
2026-09-20
Completion
2027-08-30

Countries

  • India

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07555392 on ClinicalTrials.gov